1.3
The procedure should be performed under appropriate imaging guidance. 1.4 A number of devices are available, and there is some uncertainty about the energy levels that should be used. Any adverse events relating to this procedure should be reported to the Medicines and Healthcare products Regulatory Agency. 1.5 Further research on long-term survival outcomes and comparisons of microwave ablation with other ablative techniques will be useful. In contrast, a further non-randomised controlled study reported that overall survival rates following radiofrequency ablation were 96% at 1 year, 92% at 2 years and 77% at 3 years (absolute figures not presented) which were significantly higher than survival rates following microwave ablation (rates not presented) (p = 0.041). This study also found that local recurrence following radiofrequency ablation occurred in 5% of patients at 1 year, 15% at 2 years and 15% at 3 years (absolute figures not presented) which was significantly lower than following microwave ablation (rates not presented) (p = 0.042).
2.3.3
In a non-randomised controlled study of 102 patients, the mean duration of disease-free survival was 15.5 months in patients treated with microwave ablation (95% confidence interval [CI] 11.3 to 20.0 months) compared with 16.5 months (95% CI 10.1 to 19.2 months) in those receiving radiofrequency ablation. The difference was not statistically significant (p = 0.53).
2.3.4
The Specialist Advisers stated that this is a novel procedure, but there are no major concerns about efficacy. They noted that data on long-term survival are limited.
Safety

2.4.1
A non-randomised controlled trial of 89 patients found no difference in the incidence of intra-abdominal bleeding, gastrointestinal bleeding, biliary stenosis
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and wound dehiscence between patients treated with microwave ablation via laparotomy and those treated with liver resection.
2.4.2
Another non-randomised controlled trial reported that major complications A further non-randomised controlled trial found that there was a significantly greater proportion of patients with postoperative pain following microwave ablation, 16% (11/70), than following radiofrequency ablation, 4% (2/48) (p = 0.049). There was also a higher rate in the microwave ablation group than in the radiofrequency group of patients with bile duct injury, 16% (11/70) versus 4%
(2/48) (p = 0.049), and postoperative ascites, 10% (7/70) versus 0% (p = 0.024).
However, there were no statistically significant differences in the rates of skin burns, vagovagal reflex, liver abscess, bleeding, hepatic infarction, portal thrombus or biliary peritonitis between treatment groups. 
Sources of evidence
The evidence considered by the Interventional Procedures Advisory Committee is described in the following document.
'Interventional procedure overview of microwave ablation of hepatocellular carcinoma', August
2006.
Information for patients
The Institute has produced information describing its guidance on this procedure for patients ('Understanding NICE guidance'). It explains the nature of the procedure and the decision made, and has been written with patient consent in mind. This guidance was developed using the NICE interventional procedure guidance process.
We have produced a summary of this guidance for patients and carers. Information about the evidence it is based on is also available.
Changes since publication Changes since publication 16 January 2012: minor maintenance.
Y Your responsibility our responsibility
This guidance represents the views of NICE and was arrived at after careful consideration of the available evidence. Healthcare professionals are expected to take it fully into account when exercising their clinical judgement. This guidance does not, however, override the individual Microwave ablation of hepatocellular carcinoma (IPG214)
